Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thiopurine continuation versus withdrawal during switch from intravenous to subcutaneous infliximab in inflammatory bowel disease
ISRCTN95420128Phase 4Completed
- Sponsor
- King's Health Partners
- Start
- Oct 2022
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of infliximab, azathioprine and mercaptopurine in Crohn's disease, autoimmune colitis and inflammatory bowel disease (IBD) (2 arms), sponsored by King's Health Partners. Primary endpoint: Free anti-drug antibody positivity at week 24. Started Oct 2022; status: completed.
02
Drugs
infliximabazathioprinemercaptopurine
03
Conditions
Crohn's diseaseautoimmune colitisinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on ISRCTN95420128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN95420128.